Loss of insulin receptor substrate-1 signaling induces the cardiovascular and proteo(fibrino)lytic system derangements typical of insulin resistance

Coronary Artery Disease

Volumn 16, Issue 2, 2005, Pages 117-123

  Furumoto, Tomoo ^a   Fujii, Satoshi ^a,e   Onozuka, Hisao ^a   Zaman, A K M Tarikuz ^a   Goto, Daisuke ^a   Sugawara, Taeko ^a   Mikami, Taisei ^a   Watanabe, Satoshi ^a   Abe, Kazuhiro ^b   Terauchi, Yasuo ^c   Kadowaki, Takashi ^c   Kitabatake, Akira ^a   Sobel, Burton E ^d  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HEALTH SCIENCES UNIVERSITY OF HOKKAIDO   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^e HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Diabetes; Insulin resistance; Signal transduction; Thrombolysis; Thrombosis

Indexed keywords

INSULIN RECEPTOR SUBSTRATE 1; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY WALL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ECHOCARDIOGRAPHY; FIBRINOLYSIS; HEART DISEASE; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE SIZE; IMMUNOHISTOCHEMISTRY; INSULIN RESISTANCE; KNOCKOUT MOUSE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION; TUNICA MEDIA; VASCULAR FIBROSIS;

ANIMALS; BIOLOGICAL MARKERS; BLOTTING, NORTHERN; CORONARY VESSELS; DISEASE MODELS, ANIMAL; ECHOCARDIOGRAPHY; FIBROSIS; GENE EXPRESSION; HEART FAILURE, CONGESTIVE; IMMUNOENZYME TECHNIQUES; INSULIN RESISTANCE; MICE; MICE, INBRED C57BL; MYOCARDIAL CONTRACTION; MYOCARDIUM; PHENOTYPE; PHOSPHOPROTEINS; PLASMINOGEN ACTIVATOR INHIBITOR 1; RNA; SIGNAL TRANSDUCTION;

EID: 20144363068     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-200503000-00007     Document Type: Article

References (32)

1. Haffner SM, Lehto S, Rönnemaa T, Pyorala K, Laasko M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339:229-234.
2. McGill J, Schneider D, Arfken C, Lucore C, Sobel B. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes 1994; 43:104-109.
3. Wiman B. Plasminogen activator inhibitor 1 (PAI-1) in plasma: its role in thrombotic disease. Thromb Haemost 1995; 74:71-76.
4. Mansfield M, Stickland M, Grant P. Plasminogen activator inhibitor-1 (PAI-1) promoter polymorphism and coronary artery disease in non-insulin-dependent diabetes. Thromb Haemost 1995; 74:1032-1034.
5. Sobel B, Woodcock-Mitchell J, Schneider D, Holt R, Marutsuka K, Gold H. Increased plasminogen activator inhibitor type-1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence. Circulation 1998; 97:2213-2221.
6. Pandolfi A, Cetrullo D, Polishuck R, Alberta M, Calafiore A, Pellegrini G, et al. Plasminogen activator inhibitor type 2 is increased in the arterial wall of type II diabetic subjects. Arterioscler Thromb Vasc Biol 2001; 8:1378-1382.
7. Zaman A, Fujii S, Sawa H, Goto D, Ishimori N, Watano K, et al. Angiotensin-converting enzyme inhibition attenuates hypofibrinolysis and reduces cardiac perivascular fibrosis in genetically obese diabetic mice. Circulation 2001; 103:3123-3128.
8. Piccini J, Klein L, Gheorghiade M, Bonow R. New insights into diastolic heart failure: role of diabetes mellitus. Am J Med 2004; 116(suppl 5A):64S-75S.
9. Cittadini A, Mantzoros C, Hampton T, Travers K, Katz S, Morgan J, et al. Cardiovascular abnormalities in transgenic mice with reduced brown fat: an animal model of human obesity. Circulation 1999; 100:2177-2183.
10. Fang Z, Prins J, Marwick T. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implication. Endocr Rev 2004; 25:543-567.
11. Fredersdorf S, Thumann C, Ulucan C, Griese D, Luchner A, Riegger G, et al. Myocardial hypertrophy and enhanced left ventricular contractility in Zucker diabetic fatty rats. Cardiovasc Pathol 2004; 13:11-19.
12. Yu Y, Ohmori K, Kondo I, Yao L, Noma T, Tsuji T, et al. Correlation of functional and structural alterations of the coronary arterioles during development of type II diabetes mellitus in rats. Cardiovasc Res 2002; 56:303-311.
13. Okada H, Nordt T, Lundgren CH, Fujii S. Human aortic vascular smooth muscle cells digest extracellular matrix by elaboration of plasminogen activators: implications for atherogenesis. J Thromb Thrombol 1995; 2:107-112.
14. Sobel B. Increased plasminogen activator inhibitor-1 and vasculopathy. A reconcilable paradox. Circulation 1999; 99:2496-2498.
15. Sobel B, Taatjes D, Schneider D. Intramural plasminogen activator inhibitor type-1 and coronary atherosclerosis. Arterioscler Thromb Vasc Biol 2003; 23:1979-1989.
16. Schneider D, Hayes M, Wadsworth M, Taatjes H, Rincon M, Taatjes D, et al. Attenuation of neointimal vascular smooth muscle cellularity in atheroma by plasminogen activator inhibitor type-1 (PAI-1). J Histochem Cytochem 2004; 52:1091-1099.
17. Tamemoto H, Kadowaki T, Tobe K, Yagi T, Sakura H, Hayakawa T, et al. Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. Nature 1994; 372:182-186.
18. Lundgren C, Sawa H, Sobel B, Fujii S. Modulation of expression of monocyte/macrophage plasminogen activator activity and its implications for attenuation of vasculopathy. Circulation 1994; 90:1927-1934.
19. Onozuka H, Fujii S, Mikami T, Yamada S, Ishimori N, Shimizu T, et al. In vivo echocardiographic detection of cardiovascular lesions in apolipoprotein E-knockout mice using a novel high-frequency high-speed echocardiography technique. Circ J 2002; 66:272-276.
20. Abe H, Yamada N, Kamata K, Shimada M, Osuga J, Shionoiri F, et al. Hypertension, hypertriglyceridemia, and impaired endothelium-dependent vascular relaxation in mice lacking insulin receptor substrate-1. J Clin Invest 1998; 101:1784-1788.
21. Belke D, Betuing S, Tuttle M, Graveleau C, Young ME, Pham M, et al. Insulin signaling coordinately regulates cardiac size, metabolism, and contractile protein isoform expression. J Clin Invest 2002; 109:629-639.
22. Tobe K, Tamemoto H, Yamauchi T, Aizawa S, Yazaki Y, Kadowaki T. Identification of a 190-kDa protein as a novel substrate for the insulin receptor kinase functionally similar to insulin receptor substrate-1. J Biol Chem 1995; 270:5698-5701.
23. Araki E, Lipes M, Patti M, Bruning J, Haag B 3rd, Johnson R, et al. Alternative pathway of insulin signaling in mice with targeted disruption of the IRS-1 gene. Nature 1994; 372:186-190.
24. Yamauchi T, Tobe K, Tamemoto H, Ueki K, Kaburagi Y, Yamamoto-Honda R, et al. Insulin signaling and insulin actions in the muscles and livers of insulin-resistant, insulin receptor substrate 1-deficient mice. Mol Cell Biol 1996; 16:3074-3084.
25. Peng L, Bhatia N, Parker AC, Zhu Y, Fay W. Endogenous vitronectin and plasminogen activator inhibitor-1 promote neointima formation in murine carotid arteries. Arterioscler Thromb Vasc Biol 2002; 22:934-939.
26. Eren M, Painter C, Atkinson J, Declerk P, Vaughan D. Age-dependent spontaneous coronary arterial thrombosis in transgenic mice that express a stable form of human plasminogen activator inhibitor-1. Circulation 2002; 106:491-496.
27. Schneider D, Sobel B. Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type I: implications for vascular disease in hyperinsulinemic states. Proc Natl Acad Sci USA 1991; 88:9959-9963.
28. Nordt T, Sawa H, Fujii S, Bode C, Sobel B. Augmentation of arterial endothelial cell expression of the plasminogen activator inhibitor type-1 (PAI-1) gene by proinsulin and insulin in vivo. J Mol Cell Cardiol 1998; 30:1535-1543.
29. Kaikita K, Fogo A, Ma L, Schoenhard J, Brown N, Vaughan D. Plasminogen activator inhibitor-1 deficiency prevents hypertension and vascular fibrosis in response to long-term nitric oxide synthase inhibition. Circulation 2001; 104:839-844.
30. Kubota T, Kubota N, Moroi M, Terauchi Y, Kobayashi T, Kamata K, et al. Lack of insulin receptor substrate-2 causes progressive neointima formation in response to vessel injury. Circulation 2003; 107:3073-3080.
31. Yonezawa T, Umemoto S, Fujii A, Katayama K, Matsuzaki M. Comparative effects of type 1 angiotensin II-receptor blockade with angiotensin-converting- enzyme inhibitor on left ventricular distensibility and collagen metabolism in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1996; 27:119-124.
32. Mizushige K, Yao L, Noma T, Kiyomoto H, Yu Y, Hosomi N, et al. Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model. Circulation 2000; 101:899-907.